NEW YORK, NY / ACCESSWIRE / December 28, 2020 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.

Zosano Pharma Corporation (NASDAQ:ZSAN)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/zosano-pharma-corporation-loss-submission-form?prid=11818&wire=1
Lead Plaintiff Deadline: December 28, 2020
Class Period: February 13, 2017 - September 30, 2020

Allegations against ZSAN include that: (1) the Company's clinical results reflected differences in zolmitriptan exposures observed between subjects receiving different lots; (2) pharmocokinetic studies submitted in connection with the Company's New Drug Application included patients exhibiting unexpected high plasma concentrations of zolmitriptan; (3) as a result of the foregoing differences among patient results, the U.S. Food and Drug Administration was reasonably likely to require further studies to support regulatory approval of the Company's lead product candidate, Qtrypta; (4) as a result, regulatory approval of Qtrypta was reasonably likely to be delayed; and (5) as a result of the foregoing, Defendants' public statements were materially false and misleading at all relevant times.

HP Inc. (NYSE:HPQ)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/hp-inc-loss-submission-form-2?prid=11818&wire=1
Lead Plaintiff Deadline: January 4, 2021
Class Period: November 6, 2015 - June 21, 2016

Allegations against HPQ include that: (a) HP's channel inventory management and sales practices resulted in the sale of supplies to customers that did not need or want the product in order to artificially increase revenues and profits; (b) HP's channel inventory management and sales practices resulted in the sale of supplies to customers outside of designated regions at unsustainable discounts in order to artificially increase revenues and profits; (c) HP's channel inventory management and sales practices resulted in the sale of supplies at steep discounts to customers to encourage those customers to sell the supplies further down the supply channel, out of HP's inventory management metrics; and (d) as a result of (a)-(c) above, defendants' statements about HP's business condition and prospects were materially false and misleading when made.

GoodRx Holdings, Inc (NASDAQ:GDRX)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/goodrx-holdings-inc-loss-submission-form?prid=11818&wire=1
Lead Plaintiff Deadline: February 16, 2021
Class Period: September 23, 2020 - November 16, 2020